New Class of Drug Therapies with Low Toxicity Treating HER2-Positive Breast Cancer
Women with HER2 positive breast cancer used to have a poorer prognosis. While it is still a serious breast cancer subtype, the latest news from ASCO shows yet another promising drug to knock the cancer back and Dr. Julie Gralow, director of medical oncology at the University of Washington and the Seattle Cancer Alliance says it is big news. In this video, Dr. Gralow also comments on research for women with the “triple negative” subtype and also about preventing the bone complications of advanced breast cancer.
Experts & Guests
Julie Gralow, M.D.
Director of Breast Medical Oncology, Seattle Cancer Care AllianceDr. Julie Gralow is Director of Breast Medical Oncology at Seattle Cancer Care Alliance and is an associate professor in the oncology division at University of Washington School of Medicine. She received her medical degree from the University of Southern California in Los Angeles. Dr. Gralow’s specialty and research focus is breast cancer. more >